Author Archives: Guest Blogger
By Guest Blogger | Published: April 4, 2014
In 1995, there were 16 million internet users — or 0.4% of the world’s population. In just 17 years, this figure has grown to 2.4 billion and 34.3% adoption. At the current rate, each year, the penetration percentage sees a 2–4% growth. Many services, such as banking, have moved towards online service models, shutting down branch […]
Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
By Lisa Henderson, Applied Clinical Trials. In January 2013, FDA told manufacturers to lower the dose of zolpidem, the insomnia treatment, for women, and suggested a 10 mg to 5 mg for immediate-release products (Ambien, Edluar, and Zolpimist) and from 12.5 mg to 6.25 mg for extended-release products (Ambien CR). That was based on evidence […]
by Andrew Spong (originally published on stwem.com) The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse. It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry. It has everything to do with the […]
By Guest Blogger | Published: March 31, 2014
By Morten Hjemlsoe. One of the questions I’m increasingly being asked at conferences is, “What’s next after CLM?” That’s actually rather nice to hear. To me, the question is like those delightful birds, the swallows, whose appearance announces that spring is on its way: it signifies that we’re ready for things to change.